Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr

To clarify whether the rate of decline in stimulated C‐peptide (SCP) from 2 to 15 months after diagnosis has changed over an interval of 27 yr.

[1]  R. Hamman,et al.  Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study , 2012, Diabetologia.

[2]  Å. Lernmark,et al.  Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C‐peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes , 2012, Pediatric diabetes.

[3]  M. Atkinson,et al.  Formation of a human β-cell population within pancreatic islets is set early in life. , 2012, The Journal of clinical endocrinology and metabolism.

[4]  P. Bingley,et al.  Trends in childhood type 1 diabetes incidence in Europe during 1989–2008: evidence of non-uniformity over time in rates of increase , 2012, Diabetologia.

[5]  M. Knip.  Descriptive epidemiology of type 1 diabetes—is it still in? , 2012, Diabetologia.

[6]  M. Rewers,et al.  The interplay of autoimmunity and insulin resistance in type 1 diabetes. , 2012, Discovery medicine.

[7]  Darrell M. Wilson,et al.  Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[8]  L. Nyström,et al.  Incidence of Type 1 Diabetes in Sweden Among Individuals Aged 0–34 Years, 1983–2007 , 2011, Diabetes Care.

[9]  M. Blössner,et al.  Global prevalence and trends of overweight and obesity among preschool children. , 2010, The American journal of clinical nutrition.

[10]  Darrell M. Wilson,et al.  Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes , 2010, Diabetes Care.

[11]  Darrell M. Wilson,et al.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. , 2009, The New England journal of medicine.

[12]  C. de Beaufort,et al.  Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta‐cell function and glycemic control 12 months after diagnosis , 2009, Pediatric diabetes.

[13]  H. Mortensen,et al.  Long‐term trends in the incidence of type 1 diabetes in Denmark: the seasonal variation changes over time , 2009, Pediatric diabetes.

[14]  J. Krischer,et al.  Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 , 2008, Diabetes Care.

[15]  M. Nordwall,et al.  Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years , 2008, Diabetes/metabolism research and reviews.

[16]  R. Rizza,et al.  β-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of β-Cell Mass in Humans , 2008, Diabetes.

[17]  R. Mirmira.  Faculty Opinions recommendation of Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. , 2008 .

[18]  J. Tuomilehto,et al.  Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999 , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[19]  J. Krischer,et al.  Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. , 2006, Diabetes care.

[20]  G. Dahlquist,et al.  Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983–2000 , 2004, Acta paediatrica.

[21]  C. Berne,et al.  Temporary Preservation of β-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes , 2004 .

[22]  J. She,et al.  Preservation of C‐peptide secretion in subjects at high risk of developing type 1 diabetes mellitus – a new surrogate measure of non‐progression? , 2004, Pediatric diabetes.

[23]  M. Steffes,et al.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. , 2003, Diabetes care.

[24]  T. Wilkin.  The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes , 2001, Diabetologia.

[25]  C. Mølgaard,et al.  Body mass index of 0 to 45-y-old Danes: reference values and comparison with published European reference values , 2001, International Journal of Obesity.

[26]  T. Cole,et al.  Establishing a standard definition for child overweight and obesity worldwide: international survey , 2000, BMJ : British Medical Journal.

[27]  J. Ilonen,et al.  Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children , 1998, Diabetologia.

[28]  E. Bognetti,et al.  Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty , 1998, Acta Diabetologica.

[29]  Å. Lernmark,et al.  Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes. , 1995, Diabetes research and clinical practice.

[30]  J. Jeppsson,et al.  Improved Method for Analysis of Glycated Haemoglobin by Ion Exchange Chromatography , 1994, Annals of clinical biochemistry.

[31]  Å. Lernmark,et al.  Improved Specificity of ICA Assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop , 1992, Diabetes.

[32]  Å. Lernmark,et al.  Factors influencing the magnitude, duration, and rate of fall of B-cell function in Type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis , 1988, Diabetologia.

[33]  E. Andersen,et al.  [Heights and weights of Danish children]. , 1982, Ugeskrift for laeger.

[34]  Darrell M. Wilson,et al.  Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes Running title: MMF and DZB in New Onset T1D , 2010 .

[35]  G. Dahlquist.  Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis , 2005, Diabetologia.

[36]  C. Berne,et al.  Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. , 2004, Diabetes care.

[37]  Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. , 1998, Annals of internal medicine.

[38]  Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. , 1987, The Journal of clinical endocrinology and metabolism.